All In Biotech

Drug Trial Radar · NCT03781986

APG-115 in Salivary Gland Cancer Trial

A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in p53 Wild-type Salivary Gland Carcinoma

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

41

Actual

Start

Oct 28, 2019

Primary completion

Jan 19, 2026

Study completion Jan 2027

Sponsor

Lead sponsor
University of Michigan Rogel Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ascentage Pharma Group Inc.
First posted
Dec 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II trial to evaluate the efficacy of APG-115 +/- Carboplatin for the treatment p53 wild-type malignant salivary gland cancer. Part 1 consisted of 2 arms, arm A (APG-115 monotherapy) and arm B (APG-115 + Carboplatin) and was terminated early. Part 2 is a single arm study (APG-115 monotherapy).

Conditions

  • Malignant Salivary Gland Cancer
  • Salivary Gland Cancer

Interventions

  • APG-115Drug

    APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.

  • CarboplatinDrug

    Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Toxicity Endpoint: dose-limiting toxicity (DLT)Time frame: 42 days
  2. Maximally tolerated dose (MTD)Time frame: 42 days
  3. Overall response rateTime frame: up to 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Chicago

    Chicago, Illinois

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.